A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Pazopanib (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 11 Aug 2011 Actual end date changed from May 2010 to Mar 2011 as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.